Navigation Links
Mach One Corporation Enters Letter of Intent
Date:1/5/2009

BELGIUM, Wis., Jan. 5 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a biological solutions company that develops products that produce a positive long term benefit to the agricultural and consumer market, announced today that it has entered into a non-binding letter of intent dated December 30, 2008 related to a proposed transaction with Modular Process Constructors LLC (dba MPS BioPharm) (the "Seller" or "BioPharm") to acquire all of the outstanding member interests of the Seller.

The proposed transaction is subject to satisfactory completion of due diligence by the Purchaser, the execution of a definitive agreement and the approval of both the board of directors and the members of Seller.

The non-binding terms of the letter of intent provide that all members of Seller would receive shares of the Purchaser in exchange for 100% of their interest of BioPharm. The terms include issuance of preferred stock with conversion rights at .25 per share in Mach One Corporation common stock.

There can be no assurance that any definitive agreement will be entered into, that any proposed transaction will be approved by the members of BioPharm or that any transaction will be completed as a result of the execution of the letter of intent.

Monte Tobin, CEO of Mach One Corporation commented, "This proposed acquisition of Modular Process Constructors, a systems company supplying pharmaceutical companies with processing skids, would fill out an important part of our future growth plans- dealing with world class customers and increasing our presence in the pharmaceutical space. Our business plan calls for us to eventually provide our Bridge(TM) product line into the human market and an acquisition now of BioPharm poises us for that future event on a global scale. This marks our third transaction in the 4th quarter with each transaction occurring at a substantially higher price. We anticipate our corporate development activities will continue to take place at increasingly higher valuations (non-dilutive) utilizing both organic and acquisition growth."

About Modular Process Constructors LLC (dba MPS BioPharm)

MPS BioPharm currently designs and builds skid based solutions to the biopharmaceutical markets. These skids allow the acceleration of production of biopharmaceutical products on a global basis.

About Mach One Corporation:

Mach One (www.machonecorp.com) currently manufactures and sells Bridge (TM) , a colostrums replacement, supplement and prophylactic, in sterile powder form, which can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market that includes an added ingredient for elimination of mastitis and Johnnes disease.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):